Mereo BioPharma Q2 FY26 net loss narrows to $7 million; R&D expenses drop to $1.81 million

Reuters2026/08/11 12:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Mereo BioPharma posted a Q2 2026 net loss of $7.01 million, narrowing from a $14.62 million loss a year earlier.
R&D expense fell to $1.81 million from $5.37 million, due to lower setrusumab and alvelestat program spending.
G&A expense edged down to $5.22 million from $5.49 million, on delayed pre-commercial investment for setrusumab in Europe.
Cash and cash equivalents declined to $30.12 million at June 30, 2026; cash runway is now expected to extend into late 2027.
Entered an option and license deal with Sentynl for U.S. rights to alvelestat; Phase 3 is planned for early 2027 if the option is exercised.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mereo BioPharma Group plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110815PRIMZONEFULLFEED9807674) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Mereo BioPharma Q2 FY26 net loss narrows to $7 million; R&D expenses drop to $1.81 million

You may also like

Crypto prices